SEC Form 4 · accession 0001127602-15-000618
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yarlagadda S Babu
Officer — Senior VP - Drug Discovery
Period of report
Jan 1, 2015
Accepted (ET)
Jan 5, 2015 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 1, 2015 | A | 8,900 | $0.00 | A | 217,095 | D | |
| Common StockF2 | Jan 1, 2015 | F | 2,402 | $12.16 | D | 214,693 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy)F3 | $12.16 | Jan 1, 2015 | A | 42,400 | A | Jan 1, 2016 | Jan 1, 2025 | Common Stock | 42,400 | 42,400 | D |
Explanation of responses
- F1Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- F2Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013.
- F3Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.